Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ORBIVAC

Financiado

Cerrado

Development of Vaccines for bTV EHDV and AHSV

The major outstanding challenges of orbivirus vaccine research is to develop vaccines that can afford a broad protective immune response against as many serotypes of each virus as possible, and to develop a high throughput DIVA as... ver más

31/01/2014

LSHTM

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-01-31 No tenemos la información de la convocatoria

0% 72% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

LSHTM

0.00€ | Lider

IDvet

N.D. | Participante

BIV

N.D. | Participante

FLI

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICIN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The major outstanding challenges of orbivirus vaccine research is to develop vaccines that can afford a broad protective immune response against as many serotypes of each virus as possible, and to develop a high throughput DIVA assay (e.g. an ELISA). This project will use a coordinated multipartner approach to address these issues, to develop new experimental prototype vaccines and diagnostic approaches. It will build on specific expertise and reagents that are only available within the consortium and will link out to other international efforts in USA and South Africa to develop improved vaccines for these diseases. The consortium includes a number of industrial partners who are already active in vaccine manufacture for these and other veterinary diseases, in order to ensure that the findings of the research are transferred as soon as possible into commercial vaccines for European livestock. The project also includes two SMEs, who will be specifically involved in the development of DIVA compatible diagnostic tests. In summary, the specific objectives of the project will be: to develop multivalent vaccines using different approaches for Orbiviruses responsible for livestock diseases, in particular, Bluetongue Virus (BTV), African Horse Sickness Virus (AHSV) and Epizootic Haemorrhagic Disease Virus (EHDV); to understand the best vaccination strategy to elicit multi-serotype protection for these viruses in livestock and analyze immune responses for each of the novel vaccines developed for breadth of protection against multiple serotypes; and to develop DIVA compatible diagnostics that will work with the new vaccines developed in order to differentiate between vaccinated and infected animals.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores